米拉贝隆治疗结构性心脏病:Beta3-LVH 2b期随机临床试验
Beta3-LVH是一项前瞻性、三盲、安慰剂对照2b期随机临床试验,纳入296例左心室肥厚且无或轻度心衰症状的患者,随机接受米拉贝隆50 mg/d或安慰剂治疗12个月。主要终点左室质量指数和舒张功能(E/e')组间差异均无统计学意义,米拉贝隆对左室质量或舒张功能呈中性效应。
要点
- 米拉贝隆50 mg/d治疗12个月未显著改善左室质量指数或舒张功能。
核心结论
- 在结构性心脏病且无或轻度心衰症状的患者中,米拉贝隆治疗12个月对左室质量或舒张功能呈中性效应。
研究设计与样本
- Beta3-LVH为前瞻性、三盲、安慰剂对照2b期随机临床试验,2016年9月12日至2021年2月26日纳入患者,随访12个月。
- 研究在8个欧洲国家的10家学术医院开展。
- 380例患者筛查后296例入组,随机分配至米拉贝隆50 mg/d组(147例)或安慰剂组(149例),按房颤和/或2型糖尿病分层。
- 入选标准为年龄18岁及以上、NYHA心功能分级不超过II级,超声心动图显示左室质量指数增高(女性≥95 g/m2,男性≥115 g/m2)或最大室壁厚度≥13 mm。
- 主要终点为12个月时心脏磁共振测定的左室质量指数和超声多普勒测定的E/e'比值。
主要发现
- 米拉贝隆组82例患者发生213次不良事件(其中19例发生31次严重不良事件),安慰剂组88例患者发生215次不良事件(其中22例发生30次严重不良事件)。
- 试验期间无死亡发生。
临床怎么用
- 本研究结果不支持使用米拉贝隆来预防结构性心脏病患者左室肥厚或舒张功能的进展。
- 米拉贝隆50 mg/d在该人群中安全性与其他不良事件谱与安慰剂相似,但无心脏结构或功能获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Left ventricular (LV) hypertrophy contributes to the onset and progression of heart failure (HF), particularly for patients with pre-HF (stage B) for whom no treatment has yet proven effective to prevent transition to overt HF (stage C). The β3-adrenergic receptors (β3ARs) may represent a new target, as their activation attenuates LV remodeling. OBJECTIVE: To determine whether activation of β3ARs by repurposing a β3AR agonist, mirabegron, is safe and effective in preventing progression of LV hypertrophy and diastolic dysfunction among patients with pre- or mild HF. DESIGN, SETTING, AND PARTICIPANTS: The Beta3-LVH prospective, triple-blind, placebo-controlled phase 2b randomized clinical trial enrolled patients between September 12, 2016, and February 26, 2021, with a follow-up of 12 months. The trial was conducted at 10 academic hospitals in 8 countries across Europe (Germany, Poland, France, Belgium, Italy, Portugal, Greece, and the UK). Patients aged 18 years or older with or without HF symptoms (maximum New York Heart Association class II) were screened for the presence of LV hypertrophy (increased LV mass index [LVMI] of ≥95 g/m2 for women or ≥115 g/m2 for men) or maximum wall thickness of 13 mm or greater using echocardiography. Data analysis was performed in August 2022. INTERVENTION: Participants were randomly assigned (1:1) to mirabegron (50 mg/d) or placebo, stratified by the presence of atrial fibrillation and/or type 2 diabetes, for 12 months. MAIN OUTCOMES AND MEASURES: The primary end points were LVMI determined using cardiac magnetic resonance imaging and LV diastolic function (early diastolic tissue Doppler velocity [E/e'] ratio assessed using Doppler echocardiography) at 12 months. Patients with at least 1 valid measurement of either primary end point were included in the primary analysis. Safety was assessed for all patients who received at least 1 dose of study medication. RESULTS: Of the 380 patients screened, 296 were enrolled in the trial. There were 147 patients randomized to mirabegron (116 men [79%]; mean [SD] age, 64.0 [10.2] years) and 149 to placebo (112 men [75%]; mean [SD] age, 62.2 [10.9] years). All patients were included in the primary intention-to-treat analysis. At 12 months, the baseline and covariate-adjusted differences between groups included a 1.3-g/m2 increase in LVMI (95% CI, -0.15 to 2.74; P = .08) and a -0.15 decrease in E/e' (95% CI, -0.69 to 0.4; P = .60). A total of 213 adverse events (AEs) occurred in 82 mirabegron-treated patients (including 31 serious AEs in 19 patients) and 215 AEs occurred in 88 placebo-treated patients (including 30 serious AEs in 22 patients). No deaths occurred during the trial. CONCLUSIONS: In this study, mirabegron therapy had a neutral effect on LV mass or diastolic function over 12 months among patients who had structural heart disease with no or mild HF symptoms. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02599480.
引用
- Balligand JL, Brito D, Brosteanu O, et al. Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 37728907. doi:10.1001/jamacardio.2023.3003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。